Roche: Ventana's scope expanded in US
(CercleFinance.com) - Roche announced on Thursday that the US FDA has approved an expansion of the scope of Ventana MMR RxDx, its companion cancer diagnostic tool.
The panel's approval covers the identification of solid tumour patients with a DNA repair system defect (dMMR) eligible for treatment with Merck's Keytruda immunotherapy.
It also includes patients with endometrial cancer characterised by a tumour with a functioning MMR system who may also benefit from treatment with Keytruda.
Endometrial cancer is the most common gynaecological cancer in the US and the fourth most common cancer in women in North America.
Copyright (c) 2022 CercleFinance.com. All rights reserved.